Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines

Patricia L. Earl*, Catherine Cotter, Bernard Moss, Thomas VanCott, Jeffrey Currier, Leigh Anne Eller, Francine McCutchan, Deborah L. Birx, Nelson L. Michael, Mary A. Marovich, Merlin Robb, Josephine H. Cox

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Recombinant modified vaccinia virus Ankara (rMVA) expressing HIV-1 genes are promising vaccine candidates. Toward the goal of conducting clinical trials with one or a cocktail of recombinant viruses, four rMVAs expressing env and gag-pol genes from primary HIV-1 isolates representing predominant subtypes from Kenya, Tanzania, Uganda, and Thailand (A, C, D, and CRF01_AE, respectively) were constructed. Efficient expression, processing, and function of Env and Gag were demonstrated. All inserted genes were shown to be genetically stable after repeated passage in cell culture. Strong HIV-specific cellular and humoral immune responses were elicited in mice immunized with each individual vaccine candidate. The MVA/CMDR vaccine candidate expressing CRF01_AE genes has elicited HIV-specific T-cell responses in two independent Phase I clinical trials. Further testing of the other rMVA is warranted.

Original languageEnglish
Pages (from-to)5885-5895
Number of pages11
Issue number42
StatePublished - 25 Sep 2009
Externally publishedYes


  • HIV vaccine
  • Immune response
  • MVA


Dive into the research topics of 'Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines'. Together they form a unique fingerprint.

Cite this